Table 1.
Characteristic | Value |
---|---|
Age – median (IQR) | 43 (33-48) |
Male – N (%) | 17 (81) |
Ethnicity – N (%) | |
Black | 6 (29) |
White | 15 (71) |
Duration of HIV diagnosis – median years (IQR) | 15 (3-22) |
Baseline HIV viral load, copies/mL – median (IQR) | 2635 (0-123137) |
Patients with baseline HIV viremia (N=15) | 36267 (2206-204478) |
Baseline CD4 count, cells/mm3 – median (IQR) | 428 (60-579) |
Patients with baseline HIV viremia (N=15) | 164 (37-447) |
Patients with baseline HIV-1 RNA < 40 copies/mL (N=6) | 564 (484-849) |
Baseline CD4 percentage – median (IQR) | 22 (8-27) |
Patients with baseline HIV viremia (N=15) | 15 (5-24) |
Patients with baseline HIV-1 RNA < 40 copies/mL (N=6) | 27 (25-35) |
Treatment-experienced – N (%) | 16 (76) |
Proportion with baseline HIV-1 RNA <40 copies/mL – N (%) | 6 (38) |
Years since starting ARV therapy – median (IQR) | 14 (11-17) |
Number of prior regimens – median (IQR) | 3 (2-5.5) |
ARV pill burden – median (IQR) | 5 (3-7) |
Proportion with ARV dosing frequency ≥ twice daily – N (%) | 11 (69) |
Total pill burden with concurrent meds – median (IQR) | 7.5 (6-9) |
Number of baseline resistance mutations – median (IQR) | |
NRTI | 2 (1-4) |
NNRTI | 1 (1-2) |
PI | 1 (0-3) |
INSTI | 0 (0) |
Number of patients with NRTI-associated mutations – N (%) | |
Thymidine analogue mutations (TAMs)a | 13 (62) |
1 TAM | 2 (10) |
2 TAMs | 7 (33) |
3 or more TAMs | 4 (19) |
K65R, 69-insertion complex or Q151M complex | 0 (0) |
L74V/I | 2 (10) |
M184V/I | 11 (52) |
M184V/I with any other major NRTI mutation | 7 (33) |
No documented NRTI mutations | 3 (14) |
Number of patients with DRV-associated mutations – N (%) | |
L33F | 4 (19) |
Reasons for initiating TDF/FTC/EVG/cobi plus DRVb – N (%) | |
Treatment-experienced patients | |
Simplification for pill burden | 14 (67) |
Simplification for dosing frequency | 11 (52) |
Non-adherence to previous regimen | 6 (29) |
Virologic failure to previous regimen | 5 (24) |
Toxicity/intolerance to previous regimen | 3 (14) |
Treatment-naïve patients | |
Baseline resistance | 5 (24) |
Abbreviations: ARV, antiretroviral; DRV, darunavir; INSTI, integrase strand transfer inhibitor; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDF/FTC/EVG/cobi plus DRV, tenofovir disoproxil fumarate, emtricitabine, and cobicistat-boosted elvitegravir plus darunavir.
aTAMs include mutations and revertants at codons 41, 67, 70, 210, 215, and 219.
bReasons among treatment-experienced patients are not mutually exclusive.